The tRNA-derived fragment signature in lung cancer

Cingaram, Pradeep Reddy

doi:10.1016/j.omto.2022.09.002

Cited by 3 publications

(2 citation statements)

References 5 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They performed small RNA sequencing and PCR validation on plasma samples from 50 patients with lung adenocarcinoma and 60 healthy individuals. Their research confirmed the diagnostic value of 11 tsRNAs for lung adenocarcinoma [ 34 , 35 ].…”

Section: Discussionmentioning

confidence: 65%

Epigallocatechin gallate modulates ferroptosis through downregulation of tsRNA-13502 in non-small cell lung cancer

Wang,

et al. 2024

Cancer Cell Int

View full text Add to dashboard Cite

Ferroptosis, an iron-dependent regulated cell death mechanism, holds significant promise as a therapeutic strategy in oncology. In the current study, we explored the regulatory effects of epigallocatechin gallate (EGCG), a prominent polyphenol in green tea, on ferroptosis and its potential therapeutic implications for non-small cell lung cancer (NSCLC). Treatment of NSCLC cell lines with varying concentrations of EGCG resulted in a notable suppression of cell proliferation, as evidenced by a reduction in Ki67 immunofluorescence staining. Western blot analyses demonstrated that EGCG treatment led to a decrease in the expression of glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11) while increasing the levels of acyl-CoA synthetase long-chain family member 4 (ACSL4). These molecular changes were accompanied by an increase in intracellular iron, malondialdehyde (MDA), and reactive oxygen species (ROS), alongside ultrastructural alterations characteristic of ferroptosis. Through small RNA sequencing and RT-qPCR, transfer RNA-derived small RNA 13502 (tsRNA-13502) was identified as a significant target of EGCG action, with its expression being upregulated in NSCLC tissues compared to adjacent non-tumorous tissues. EGCG was found to modulate the ferroptosis pathway by downregulating tsRNA-13502 and altering the expression of key ferroptosis regulators (GPX4/SLC7A11 and ACSL4), thereby promoting the accumulation of iron, MDA, and ROS, and ultimately inducing ferroptosis in NSCLC cells. This study elucidates EGCG’s multifaceted mechanisms of action, underscoring the modulation of ferroptosis as a viable therapeutic approach for enhancing NSCLC treatment outcomes.

show abstract

Section: Discussionmentioning

confidence: 65%

Epigallocatechin gallate modulates ferroptosis through downregulation of tsRNA-13502 in non-small cell lung cancer

Wang,

et al. 2024

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“… 6 With the help of high-throughput sequencing and bioinformatics, scientists have found that a new class of regulatory small non-coding RNAs called tRFs are dysregulated in human diseases. 7 , 8 , 9 , 10 tRFs play important roles in many biological processes, such as stress tolerance, gene expression, gene silencing, and protein biosynthesis. Given the potential role of tRFs in human disease, Qiang and colleagues elucidated the involvement of tRF-1001 in pathological ocular angiogenesis.…”

mentioning

confidence: 99%

tRF-1001: A potential therapeutic target for ocular neovascular diseases

Cingaram¹

2023

Molecular Therapy - Nucleic Acids

Self Cite

View full text Add to dashboard Cite

tRNA‐derived fragments: Unveiling new roles and molecular mechanisms in cancer progression

Lu,

Zhu,

Zhang

et al. 2024

Intl Journal of Cancer

View full text Add to dashboard Cite

AbstracttRNA‐derived fragments (tRFs) are novel small noncoding RNAs (sncRNAs) that range from approximately 14 to 50 nt. They are generated by the cleavage of mature tRNAs or precursor tRNAs (pre‐tRNAs) at specific sites. Based on their origin and length, tRFs can be classified into three categories: (1) tRF‐1 s; (2) tRF‐3 s, tRF‐5 s, and internal tRFs (i‐tRFs); and (3) tRNA halves. They play important roles in stress response, signal transduction, and gene expression processes. Recent studies have identified differential expression of tRFs in various tumors. Aberrantly expressed tRFs have critical clinical value and show promise as new biomarkers for tumor diagnosis and prognosis and as therapeutic targets. tRFs regulate the malignant progression of tumors via various mechanisms, primarily including modulation of noncoding RNA biogenesis, global chromatin organization, gene expression regulation, modulation of protein translation, regulation of epigenetic modification, and alternative splicing regulation. In conclusion, tRF‐mediated regulatory pathways could present new avenues for tumor treatment, and tRFs could serve as promising therapeutic targets for cancer therapy.

show abstract

The tRNA-derived fragment signature in lung cancer

Cited by 3 publications

References 5 publications

Epigallocatechin gallate modulates ferroptosis through downregulation of tsRNA-13502 in non-small cell lung cancer

Epigallocatechin gallate modulates ferroptosis through downregulation of tsRNA-13502 in non-small cell lung cancer

tRF-1001: A potential therapeutic target for ocular neovascular diseases

tRNA‐derived fragments: Unveiling new roles and molecular mechanisms in cancer progression

Contact Info

Product

Resources

About